Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Individualized (fMRI-guided) TMS Treatment for Depression

NCT: NCT06266390 · ACTIVE_NOT_RECRUITING

NCT IDNCT06266390
StatusACTIVE_NOT_RECRUITING
Start Date2024-05-29
Completion2026-06-30

Brief Summary

The purpose of this study is to investigate the responses of the brain region known as the subgenual anterior cingulate cortex (sgACC) during transcranial magnetic stimulation (TMS) in individuals with depression. Specifically, investigators aim to determine whether the sgACC is engaged when TMS is delivered to specific targets and if the engagement of sgACC changes throughout a full TMS treatment intervention. To achieve this goal, the investigators will employ a combination of TMS and Magnetic Resonance Imaging (MRI) procedures. Study participation will include completing various questionnaires, clinical assessments, receiving a full transcranial magnetic stimulation (TMS) treatment intervention (every weekday for 6 weeks), and undergoing MRI scans, both with and without concurrent TMS.

Frequently Asked Questions

What is Individualized (fMRI-guided) TMS Treatment for Depression?

Individualized (fMRI-guided) TMS Treatment for Depression is a clinical trial registered under NCT06266390. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06266390?

The current status of NCT06266390 (Individualized (fMRI-guided) TMS Treatment for Depression) is: ACTIVE_NOT_RECRUITING.

When did Individualized (fMRI-guided) TMS Treatment for Depression start?

Individualized (fMRI-guided) TMS Treatment for Depression started on 2024-05-29.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.